LIGAND PHARMACEUTICALS INCORPORATED APIC, Share-based Payment Arrangement, Increase for Cost Recognition
LIGAND PHARMACEUTICALS INCORPORATED (LGNXZ) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $13.65 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-07
- LIGAND PHARMACEUTICALS INCORPORATED apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $13.65M, a 36.57% increase year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $10.60M, a 35.22% increase year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $14.75M, a 2.80% decline year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $10.00M, a 9.61% decline year-over-year.
- LIGAND PHARMACEUTICALS INCORPORATED apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $46.85M, a 14.02% increase from fiscal 2024.
- LIGAND PHARMACEUTICALS INCORPORATED apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $41.09M, a 59.61% increase from fiscal 2023.
- LIGAND PHARMACEUTICALS INCORPORATED apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $25.74M, a 57.30% decline from fiscal 2022.
- LIGAND PHARMACEUTICALS INCORPORATED apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $60.28M, a 55.44% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $13.65M 10-Q · filed 2026-08-07 | $24.25M derived: sum of 2 quarters · filed 2026-08-07 | |||
| 2026-03-31 | $10.60M 10-Q · filed 2026-08-07 | ||||
| 2025-12-31 | $46.85M 10-K · filed 2026-02-27 | ||||
| 2025-09-30 | $14.75M 10-Q · filed 2025-11-07 | $24.74M derived: sum of 2 quarters · filed 2026-08-07 | $32.58M derived: sum of 3 quarters · filed 2026-08-07 | ||
| 2025-06-30 | $10.00M 10-Q · filed 2026-08-07 | $17.83M derived: sum of 2 quarters · filed 2026-08-07 | |||
| 2025-03-31 | $7.84M 10-Q · filed 2026-08-07 | ||||
| 2024-12-31 | $41.09M 10-K · filed 2026-02-27 | ||||
| 2024-09-30 | $15.17M 10-Q · filed 2025-11-07 | $26.23M derived: sum of 2 quarters · filed 2025-11-07 | $33.56M derived: sum of 3 quarters · filed 2025-11-07 | ||
| 2024-06-30 | $11.06M 10-Q · filed 2025-11-07 | $18.39M derived: sum of 2 quarters · filed 2025-11-07 | |||
| 2024-03-31 | $7.33M 10-Q · filed 2025-11-07 | ||||
| 2023-12-31 | $25.74M 10-K · filed 2026-02-27 | ||||
| 2023-09-30 | $6.88M 10-Q · filed 2024-11-08 | $14.09M derived: sum of 2 quarters · filed 2024-11-08 | $20.02M derived: sum of 3 quarters · filed 2024-11-08 | ||
| 2023-06-30 | $7.21M 10-Q · filed 2024-11-08 | $13.14M derived: sum of 2 quarters · filed 2024-11-08 | |||
| 2023-03-31 | $5.93M 10-Q · filed 2024-11-08 | ||||
| 2022-12-31 | $60.28M 10-K · filed 2025-02-28 | ||||
| 2022-09-30 | $12.60M 10-Q · filed 2023-11-09 | $22.10M derived: sum of 2 quarters · filed 2023-11-09 | $31.14M derived: sum of 3 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $9.50M 10-Q · filed 2023-11-09 | $18.54M derived: sum of 2 quarters · filed 2023-11-09 | |||
| 2022-03-31 | $9.04M 10-Q · filed 2023-11-09 | ||||
| 2021-12-31 | $38.78M 10-K · filed 2024-02-29 | ||||
| 2021-09-30 | $9.75M 10-Q · filed 2022-11-08 | $19.97M derived: sum of 2 quarters · filed 2022-11-08 | $28.38M derived: sum of 3 quarters · filed 2022-11-08 | ||
| 2021-06-30 | $10.22M 10-Q · filed 2022-11-08 | $18.62M derived: sum of 2 quarters · filed 2022-11-08 | |||
| 2021-03-31 | $8.40M 10-Q · filed 2022-11-08 | ||||
| 2020-12-31 | $30.73M 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | $7.74M 10-Q · filed 2021-11-09 | $15.10M derived: sum of 2 quarters · filed 2021-11-09 | $20.75M derived: sum of 3 quarters · filed 2021-11-09 | ||
| 2020-06-30 | $7.36M 10-Q · filed 2021-11-09 | $13.01M derived: sum of 2 quarters · filed 2021-11-09 | |||
| 2020-03-31 | $5.65M 10-Q · filed 2021-11-09 | ||||
| 2019-12-31 | $24.52M 10-K · filed 2022-02-28 | ||||
| 2019-09-30 | $6.30M 10-Q · filed 2020-11-06 | $12.87M derived: sum of 2 quarters · filed 2020-11-06 | $18.21M derived: sum of 3 quarters · filed 2020-11-06 | ||
| 2019-06-30 | $6.57M 10-Q · filed 2020-11-06 | $11.92M derived: sum of 2 quarters · filed 2020-11-06 | |||
| 2019-03-31 | $5.35M 10-Q · filed 2020-11-06 | ||||
| 2018-12-31 | $20.85M 10-K · filed 2021-02-24 | ||||
| 2018-09-30 | $5.47M 10-Q · filed 2019-11-08 | $10.28M derived: sum of 2 quarters · filed 2019-11-08 | $14.84M derived: sum of 3 quarters · filed 2019-11-08 | ||
| 2018-06-30 | $4.81M 10-Q · filed 2019-11-08 | $9.37M derived: sum of 2 quarters · filed 2019-11-08 | |||
| 2018-03-31 | $4.55M 10-Q · filed 2019-11-08 | ||||
| 2017-12-31 | $24.92M 10-K · filed 2020-02-27 | ||||
| 2016-12-31 | $18.89M 10-K · filed 2019-02-28 | ||||
| 2015-12-31 | $12.46M 10-K · filed 2018-03-01 | ||||
| 2014-12-31 | $11.27M 10-K · filed 2017-02-28 | $5.67M 10-K · filed 2014-12-01 | |||
| 2013-12-31 | $5.67M 10-K · filed 2016-11-14 | ||||
| 2012-12-31 | $4.07M 10-K · filed 2015-02-23 | ||||
| 2011-12-31 | $3.35M 10-K/A · filed 2014-12-12 | ||||
| 2010-12-31 | $2.33M 10-K · filed 2013-03-14 | ||||
| 2009-12-31 | $3.37M 10-K/A · filed 2012-11-14 |